Stephen M. Ansell, M.D.,  Ph.D.
Chair, Mayo Clinic Lymphoma Group
Professor of Medicine, Hematology

Saad J. Kenderian, M.B., Ch.B.
Assistant Professor of Medicine, Oncology and Immunology

M. Hassan Murad,  M.D.
Director, Mayo Clinic Evidence based Practice Center
Professor of Medicine

Locations:

• Geffen Auditorium (Live)
• Broadcast to SMH Alfred M-459 and Baldwin 4-316/Baldwin 4-516
• Mayo Clinic Health System in Waycross (Video Conference)

Lunch available outside Geffen Auditorium and SMH Alfred M-459 on a first-come, first-serve basis.

Learning Objectives:

• Review the components of an effective T-cell mediated immune response
• Identify deficiencies in the anti-tumor immune response in lymphoma
• Describe strategies to overcome the deficiencies in the anti-tumor immune response
• Identify component of CAR-T cell therapy
• Review the current status of CAR-T cell therapy
• Discuss future directions in CAR-T cell therapy
• Introduce Mayo Clinic Evidence-based Practice Center
• Identify the three assumptions of network meta-analysis
• Describe a simplified approach for reading a network meta-analysis

Financial Disclosures:

• Dr. Ansell: Grant/Research Support - Affimed, Bristol Myers Squibb, Pfizer, Regeneron, Seattle Genetics
• Dr. Kenderian: Consultant - Kiniska; Grant/Research Support - Gilead Pharma, Humanigen, Kite Pharma, Lentigen, Morphyosys, Novartis Pharma, Tolero
• Dr. Murad: None

Off Label/Investigational Uses:

• Dr. Ansell: None
• Dr. Kenderian: CART cells (myeloma, solid tumors)
• Dr. Murad: None

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s), please go here to review disclosures.